Bruce Morrison, DO
Sports Medicine · Huntingdon Valley, PANPI 1255449476
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 52 manufacturers reported payments, led by AstraZeneca at 44.4% of the total. Among sports medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,039 payments — averaging $43.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- AbbVie$10K
- Astrazeneca AB$3K
- Novo Nordisk$1K
- Pfizer$1K
- Amgen$981
- plus $8K from 46 others
Across 2 payments — averaging $1220.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
What the payments were for
- Consulting fees$6,88715%
- Speaking & faculty fees$19,80044%
- Travel & lodging$1,7064%
- Food & beverage$16,84937%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,287 in reported general payments places this provider in the 95th percentile of 311 sports medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $116,258 |
| FarxigaDapagliflozin Propanediol | 158 | $114,925 |
| OzempicSemaglutide | 101 | $108,953 |
| JardianceEmpagliflozin | 85 | $81,447 |
| JanuviaSitagliptin Phosphate | 44 | $33,988 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $27,642 |
| TrulicityDulaglutide | 23 | $25,152 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $20,609 |
| XareltoRivaroxaban | 23 | $20,086 |
| LinzessLinaclotide | 34 | $19,686 |
| TrintellixVortioxetine Hydrobromide | 17 | $14,564 |
| OxycontinOxycodone Hcl | 19 | $14,534 |
| KerendiaFinerenone | 12 | $13,848 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $11,023 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $9,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $20,102 | $146,842213 claims |
| PfizerEliquis | $1,040 | $116,258129 claims |
| Novo NordiskOzempic | $1,210 | $108,953101 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $498 | $90,887101 claims |
| MerckJanuvia, Belsomra | $146 | $39,03556 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $966 | $31,63355 claims |
| Johnson & JohnsonXarelto, Invokana | $82 | $25,90934 claims |
| Lilly USA, LLCTrulicity | $822 | $25,15223 claims |
| AbbVieLinzess | $10,153 | $19,68634 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $812 | $14,56417 claims |
| BayerKerendia | $453 | $13,84812 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $833 | $6,48613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 311 sports medicine providers in Pennsylvania.
Other sports medicine in Huntingdon Valley
- Mark AyzenbergHuntingdon Valley$13K
- Sam AkhavanPittsburgh$2.2M
- Albert LinPittsburgh$460K
- Sommer HammoudPhiladelphia$238K
- Theresa PazionisPhiladelphia$235K
- Matthew Varacallodu Bois$129K
- Matthew BestAllentown$77K
- Marco AlcalaCanonsburg$54K
- Brandon TaubergWashington$54K
- Alexander JohnsonBethlehem$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.